First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective.

Cancers (Basel) · 2021 · PMC8657179 · PMID 34885238

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The two-year survival showed a trend of an increase over time: in 2009–2011, it was 30.4% for women and 17.7% for men, while it was 35.5% for women and 26.9% for men in 2018–2019.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.